Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax plus ibrutinib in relapsed/refractory T-cell prolymphocytic leukemia
NL-OMON50080Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of venetoclax and ibrutinib in T-cell prolymphocytic leukemia (T-PLL), sponsored by AbbVie Inc. Primary endpoint: Overall response rate. Started Jul 2020; status: completed.
02
Drugs
venetoclaxibrutinib
03
Conditions
T-cell prolymphocytic leukemia (T-PLL)
Beyond the preview
Go deeper on NL-OMON50080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50080.